Breed · Horse
Appaloosa: adverse event reports
FDA breed label "Appaloosa" · single-breed animals only
FDA's database holds 297 reports where the animal's breed is given as "Appaloosa", shown here as Appaloosa: 1.6% of reports about horses. Reports on crossbred animals are left out of breed pages.
16 reports arrived in the 12 months to March 2026, up 167% from 6 in the 12 months before. A breed's count mostly mirrors how common the breed is; registration and ownership figures by breed are not public data, so no per-animal rate can be given.
By active ingredient, the drugs named most often are ivermectin + praziquantel, moxidectin and pergolide mesylate. Ivermectin + Praziquantel is named in 18.9% of this breed's reports, a larger share than in reports about all horses (14.4%).
The terms listed most often are death (8.8%), application site swelling (8.4%) and abdominal pain (7.4%). Death appears in 8.8% of reports, about the same share as in all horse reports (8.1%). 48.4% of reports stating seriousness were classed as serious, against 44.1% for horses overall.
Drugs named most often, by active ingredient
| Active ingredients recorded for the drug | Reports | Share of Appaloosa reports | Share of all horse reports |
|---|---|---|---|
| Ivermectin + Praziquantel | 56 | 18.9% | 14.4% |
| Moxidectin | 25 | 8.4% | 7.4% |
| Pergolide mesylate | 25 | 8.4% | 6.5% |
| Detomidine Hydrochloride | 22 | 7.4% | 5.6% |
| Flunixin Meglumine | 17 | 5.7% | 3.5% |
| Ivermectin | 17 | 5.7% | 4.6% |
| Pyrantel Tartrate | 16 | 5.4% | 4% |
| Omeprazole | 15 | 5.1% | 9.9% |
| Ceftiofur Crystalline Free Acid | 10 | 3.4% | 4.8% |
| Firocoxib | 8 | 2.7% | 2.6% |
| Hyaluronate Sodium | 7 | 2.4% | 2.9% |
| Ketamine Hydrochloride | 7 | 2.4% | 3.3% |
| Xylazine | 7 | 2.4% | 2.4% |
| Polysulfated Glycosaminoglycan | 6 | 2% | 2.3% |
| Ponazuril | 5 | 1.7% | 1.1% |
| Oxibendazole | 4 | 1.3% | 1.1% |
| Pentosan polysulfate sodium | 4 | 1.3% | 1% |
| Misoprostol | 3 | 1% | 0.5% |
| Moxidectin + Praziquantel | 3 | 1% | 2% |
| Ceftiofur Sodium | 2 | 0.7% | 0.7% |
Ordered by report count. Differences from the species column often come from body size (which drugs a breed is prescribed) and from how common the breed was in the years a drug sold most. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.
Signs listed in reports
share of Appaloosa reports listing the termall horse reports
- Death8.8%26
- Application site swelling[swelling where the product was applied]8.4%25
- Abdominal pain7.4%22
- Lip oedema7.1%21
- Fever6.1%18
- Anorexia[not eating]5.7%17
- Injection site swelling[swelling where the injection was given]5.7%17
- Depression[dull, quiet or withdrawn]4.7%14
- Tachypnoea[fast breathing]4.4%13
- Hypersalivation[drooling]4%12
- Diarrhoea[diarrhea]3.7%11
- Lack of efficacy - NOS[the product did not have the expected effect]3.7%11
- Lethargy[unusually tired or inactive]3.7%11
- Death by euthanasia[the animal was euthanized]3.4%10
- Behavioural disorder NOS[behaviour change, type not specified]3%9
- Collapse3%9
- Dyspnoea[difficulty breathing]3%9
- Ineffective, sedation[legacy FDA term: the product did not have the expected effect (sedation)]3%9
- Injection site abscess[abscess where the injection was given]3%9
- Injection site pain[pain where the injection was given]3%9
- Anaphylaxis[sudden severe allergic-type reaction]2.7%8
- Hyperhidrosis2.7%8
- Lameness2.7%8
- Accidental exposure[exposure that was not intended]2.4%7
Age and weight
Age of the animal
Weight of the animal
Coloured bar: Appaloosa reports. Grey bar: all horse reports.
Trend and outcomes
Reports by month FDA received them. The newest months are incomplete because FDA posts reports with a delay of three to six months.
Outcome recorded in the report
Beside all horses
| Measure | Appaloosa | All horses |
|---|---|---|
| Reports | 297 | 18,382 |
| Latest 12 months | 16 | 898 |
| Classed serious, of reports stating it | 48.4% | 44.1% |
| Death or euthanasia recorded, per 1,000 reports | 138 | 136 |
Questions about Appaloosa reports
How many FDA adverse event reports involve Appaloosas?
297 reports through March 2026, 1.6% of reports about horses; 16 in the latest 12 months.
Which drugs are named most often in Appaloosa reports?
By active ingredient: ivermectin + praziquantel (56), moxidectin (25), pergolide mesylate (25), detomidine hydrochloride (22) and flunixin meglumine (17). Brands are masked in the public data.
What signs are reported most for this breed?
death (8.8%), application site swelling (8.4%), abdominal pain (7.4%), lip oedema (7.1%) and fever (6.1%).
Is the Appaloosa more sensitive to certain drugs?
Report counts cannot answer that. They show what was reported, not what a drug did, and they are not adjusted for how many Appaloosa animals exist or were treated. Breed-related drug sensitivities that are established are described on FDA-approved labels; a veterinarian is the person to ask about an individual animal.
Why are crossbreds not included?
FDA records crossbred animals with one or more component breeds. Counting them under each component would double count, so breed pages use single-breed reports only. Crossbreds remain in the species totals.
How do I report a problem?
Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 30 Sep 2026. Breed names are FDA's labels rearranged into everyday order ("Appaloosa" becomes "Appaloosa"). No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.